Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study

F. Patti, M. P. Amato, M. Trojano, S. Bastianello, M. R. Tola, O. Picconi, S. Cilia, S. Cottone, D. Centonze, C. Gasperini

Research output: Contribution to journalArticle

Abstract

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood.Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status.Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing-remitting MS treated with subcutaneous interferon beta-1a.Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 μg subcutaneously three times weekly, and 163 received interferon beta-1a, 22 μg subcutaneously three times weekly). Mean MS Quality of Life-54 (MSQoL-54) composite scores did not change over time. There were no significant differences between groups in MSQoL-54 composite scores when patients were grouped by treatment dose and baseline cognitive status. Mean (standard deviation) Hamilton Depression Rating Scale score decreased from 6.8 (4.9) at baseline to 5.8 (5.9) at year 3. Mean total Fatigue Impact Scale scores were low (

Original languageEnglish
Pages (from-to)991-1001
Number of pages11
JournalMultiple Sclerosis Journal
Volume17
Issue number8
DOIs
Publication statusPublished - 2011

Keywords

  • cognitive function
  • depression
  • fatigue
  • interferon beta-1a
  • longitudinal study
  • quality of life
  • relapsing-remitting multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study'. Together they form a unique fingerprint.

  • Cite this